Lead generation and lead optimization processes in the discovery of selective nonpeptide neurokinin receptor antagonists

Drugs of the Future

Volumn 22, Issue 11, 1997, Pages 1235-1257

  Giardina, Giuseppe A M ^a   Raveglia, Luca F ^a   Grugni, Mario ^a  

^a SmithKline Beecham SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 IMINO 2 (2 METHOXYPHENYL)ETHYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 ONE; 2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; 3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; NEUROKININ 1 RECEPTOR; NEUROKININ 2 RECEPTOR; NEUROKININ 3 RECEPTOR; SAREDUTANT; TACHYKININ RECEPTOR ANTAGONIST;

ANXIETY; DRUG DEVELOPMENT; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; EXTRAVASATION; HUMAN; NEUROMODULATION; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0031454254     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (157)

1. Maggio, J.E. Tachykinins. Ann Rev Neurosci 1988, 11: 13-28.
2. Maggi, C.A., Patacchini, R., Rovero, P., Giachetti, A. Tachykinin receptors and tachykinin receptors antagonists. J Auton Pharmacol 1993, 13: 23-93.
3. Holzer, P. Local effector functions of capsaicin-sensitive sensory nerve endings: Involvement of tachykinins, calcitonin gene-related peptide and other neuropeptides. Neuroscience 1988, 24: 739-68.
4. Otsuka, M., Yoshioka, K. Neurotransmitter functions of mammalian tachykinins. Physiol Rev 1993, 73: 229-308.
5. Maggi, C.A., Giachetti, A., Dey, R.D., Said, S.I. Neuropeptides as regulators of airway function: Vasoactive intestinal peptide and the tachykinins. Physiol Rev 1995, 75: 277-322.
6. Maggi, C.A. Tachykinins in the autonomic nervous system. Pharm Res 1996, 33: 161-70.
7. Maggio, J.E., Mantyh, P.W., Iversen, L.L. Historical perspectives of tachykinins. In: The Tachykinin Receptors. Buch, S.H. (Ed.). Humana Press: Totowa, NJ 1994, 1-38.
8. Snider, R.M., Constantine, S.J.W., Lowe, J.A. et al. A potent non-peptide antagonist of the substance P (NK-1) receptor. Science 1991, 251: 435-7.
9. Peyronel, J.F., Truchon, A., Moutonnier, C., Garret, C. Synthesis of RP-67580, a new potent nonpeptide substance P antagonist. Bioorg & Med Chem Lett 1992, 2: 37-40.
10. Edmonds-Alt, X., Vilain, P., Goulaouic, P. et al. A potent and selective non-peptide antagonist of the neurokinin A (NK-2) receptor. Life Sci 1992, 50: PL-101-6.
11. Giardina, G.A.M., Raveglia, L.F. Neurokinin-3 receptor antagonists. Exp Opin Ther Patents 1997, 7: 307-23.
12. Mussap, C.J., Geraghty, D.P., Burcher, E. Tachykinin receptors: A radioligand binding perspective. J Neurochem 1993, 60: 1987-2009.
13. McElroy, A.B. Neurokinin receptor antagonists. Curr Opin Ther Patents 1993, 3: 1157-72.
14. Desai, M.C. Recent advances in the discovery and characterization of substance P antagonists. Exp Opin Ther Patents 1994, 4: 315-21.
15. Pritchard, M.C., Boden, P. Tachykinin NK-3 receptors: Biology and development of selective peptide and nonpeptide ligands. Drugs Fut 1995, 20: 1163-73.
16. Swain, C. Neurokinin receptor antagonists. Exp Opin Ther Patents 1996, 6: 367-78.
17. Lowe, J.A. III. Nonpeptide tachykinin antagonists: Medicinal chemistry and molecular biology. Med Res Rev 1996, 16: 527-45.
18. Swain, C.J., Hargreaves, R.J. Neurokinin receptor antagonists. In: Annual Reports in Medicinal Chemistry, Vol. 31. Bristol, J.A. (Ed.). Academic Press: San Diego 1996, 111-20.
19. Elliott, J., Seward, E.M. Neurokinin receptor antagonists. Exp Opin Ther Patents 1997, 7: 43-54.
20. Lowe, J.A. III, McLean, S. Tachykinin antagonists. Curr Pharma Des 1995, 1: 269-78.
21. Dixon, R.A.F., Strader, C.D., Sigal, I.S. Structure and function of G-protein coupled receptors. In: Annual Reports in Medicinal Chemistry, Vol. 23. Allen, R.C. (Ed.). Academic Press: San Diego 1988, 221-33.
22. O'Dowd, B.F., Lefkowitz, R.J., Caron, M.G. Structure of adrenergic and related receptors. Annu Rev Neurosci 1989, 12: 67-83.
23. Bonner, T.I. The molecular basis of muscarinic receptor diversity. Trends Neurosci 1989, 12: 148-51.
24. Takeda, Y., Chou, K.B., Takeda, J., Sachais, B.S., Krause, J.E. Molecular cloning, structure characterization and functional expression of the human substance P receptor. Biochem Biophys Res Commun 1991, 179: 1232-40.
25. Yokota, Y., Sasai, Y., Tanaka, K. et al. Molecular characterization of a functional cDNA for rat substance P receptor. J Biol Chem 1989, 254: 17649-52.
26. Hershey, A.D., Krause, J.E. Molecular characterization of a functional cDNA encoding the rat substance P receptor and expression of its mRNA. Science 1990, 247: 958-61.
27. Masu, Y., Nakayama, K., Tamaki, H., Harada, Y. Kuno, M., Nakanishi, S. cDNA cloning of bovine substance K receptor through oocyte expression system. Nature 1987, 329: 836-8.
28. Gerard, N.P., Eddy, R.L. Jr., Shows, T.B., Gerard, C. The human neurokinin A (substance K) receptor. J Biol Chem 1990, 265: 20455-62.
29. Sasai, Y., Nakanishi, S. Molecular characterization of rat substance K receptor and its mRNAs. Biochem Biophys Res Commun 1989, 165: 695-702.
30. Shigemoto, R., Yokota, Y., Tsuchida, K., Nakanishi, S. Cloning and expression of rat neuromedin K receptor cDNA. J Biol Chem 1990, 265: 623-8.
31. Buell, G., Schulz, M.F., Arkinstall, S.J. et al. Molecular characterization, expression and localization of human NK-3 receptor. FEBS Lett 1992, 299: 90-5.
32. Huang, R.-R.C., Cheung, A.M., Mazina, K.E., Strader, C.D., Fong, T.M. cDNA sequence and heterologous expression of the human neurokinin-3 receptor. Biochem Biophys Res Commun 1992, 184: 966-72.
33. Takahashi, K., Tanaka, A., Hara, M., Nakanishi, S. The primary structure and gene organization of human substance P and neuromedin K receptors. Eur J Biochem 1992, 204: 1025-33.
34. Patacchini, R., Maggi, C.A. Tachykinin receptors and receptor subtypes. Arch Int Pharmacodyn 1995, 329: 161-84.
35. Nguyen, Q.T., Jukic, D., Chetien, L., Gobeil, F., Boussougou, M., Regoli, D. Two NK-3 receptor subtypes: Demonstration by biological and binding assays. Neuropeptides 1994, 27: 157-61.
36. Medhurst, A.D., Hay D.W.P., Parsons, A.A. Evidence for NK-3 receptor subtypes in rabbit isolated iris sphincter muscle using the NK-3 receptor antagonists SR-142801 and SR-48968. Br J Pharmacol 1996, 117: 203P.
37. Donaldson, L.F., Haskell, C.A., Hanley, M.R. Functional characterization by heterologous expression of a novel cloned tachykinin peptide receptor. Biochem J 1996, 320: 1-5.
38. Tsuchida, K., Shigemoto, R., Yokota, Y., Nakanishi, S. Tissue distribution and quantification of the mRNA for three rat tachykinin receptors. Eur J Biochem 1990, 193: 751-7.
39. Elde, R., Schalling, M., Ceccatelli, S., Nakanishi, S., Hokfelt, T. Localization of neuropeptide receptor mRNA in rat brain: Initial observations using probes for neurotensine and substance P receptors. Neurosci Lett 1990, 120: 134-8.
40. Nakanishi, S. Mammalian tachykinin receptors. Annu Rev Neurosci 1991, 14: 123-36.
41. Dietl, M.M., Palacios, J.M. Phylogeny of tachykinin receptor localization in the vertebrate central nervous system. Brain Res 1991, 539: 211-22.
42. Hagan, R.M., Beresford, I.J.M., Stables, J. et al. Characterisation, CNS distribution and function of NK-2 receptors studied using potent NK-2 receptor antagonists. Regul Peptides 1993, 46: 9-19.
43. Stratton, S.C., Beresford, I.J.M., Hagan, R.M. GR-159897, a potent non-peptide tachykinin NK-2 receptor antagonist, releases suppressed behaviours in a novel aversive environment. Br J Pharmacol 1994, 112: 49P.
44. Laufer, R., Gilon, C., Chorevi, M., Selinger, Z. Characterization of a neurokinin B receptor site in rat brain using a highly selective radioligand. J Biol Chem 1986, 261: 10257-63.
45. Saffroy, M., Beaujouan, J.-C., Torrens, Y., Besseyre, J., Bergström, L., Glowinski, J. Localization of tachykinin binding sites (NK-1, NK-2, NK-3 ligands) in the rat brain. Peptides 1988, 9: 227-41.
46. 3H]-senktide. Brain Res 1990, 506: 175-9.
47. Guard, S., Watson, S.P. Tachykinin receptor types: Classification and membrane signalling mechanisms. Neurochem Int 1991, 18: 149-65.
48. Moussaoui, S.M. et al. Inhibition of neurogenic inflammation in the meninges by a non-peptide tachykinin antagonist. Eur J Pharmacol 1993, 238: 421-4.
49. Cutrer, F.M. et al. The non-peptide neurokinin-1 antagonist, RPR-100,893, decreases c-fos expression in trigeminal nucleus caudalis following noxious chemical meningeal stimulation. Neuroscience 1995, 64: 741-50.
50. Tattersall, F.D., Rycroft, W., Hill, R.G., Hargreaves, R.J. Enantioselective inhibition of apomorphine-induced emesis in the ferret by the neurokinin-1 receptor antagonist CP-99,994. Neuropharmacology 1994, 33: 259-60.
51. Watson, J.W., Gonsalves, S.F., Fossa, A.A. et al. The antiemetic effects of CP-99,994 in the ferret and the dog - Role of the NK-1 receptor. Br J Pharmacol 1995, 115: 84-94.
52. Lowe, J.A. III. Tachykinin antagonists in the treatment of asthma. Emerging Drugs 1996, 1-18.
53. Adcock, I.M., Peters, M., Gelder, C., Shirasaki, H., Brown, C.R., Barnes, P.J. Increased tachykinin receptor gene expression in asthmatic lung and its modulation by steroids. J Mol Endocrinol 1993, 11: 1-7.
54. Bai, T.R., Zhou, D., Weit, T. et al. Substance P (NK-1)- and neurokinin A (NK-2) receptor gene expression in inflammatory airway diseases. Am J Physiol 1995, 269: PL309-17.
55. Murai, M., Morimoto, H., Maeda, Y., Kiyotoh, S., Nishikawa, M., Fujii, T. Effects of FK-224, a novel compound NK-1 and NK-2 receptor antagonist, on airway constriction and airway edema induced by neurokinins and sensory nerve stimulation in guinea-pigs. J Pharmacol Exp Ther 1992, 262: 403-8.
56. Joos, G.F., Van Schoor, J., Kips, J.C., Pauwels, R.A. The effect of inhaled FK-224, a tachykinin NK-1 and NK-2 receptor antagonist on neurokinin A-induced bronchoconstriction in asthmatics. Am J Respir Crit Care Med 1996, 153: 1781-4.
57. Lembeck, F., Donnerer, J., Tsuchiya, M., Nagahisa, A. The non-peptide tachykinin antagonist, CP-96,345, is a potent inhibitor of neurogenic inflammation. Br J Pharmacol 1992, 105: 527-30.
58. Moussaoui, S.M., Montier, F., Carruette, A., Blanchard, J.C., Laduron, P.M., Garret, C. A non-peptide NK-1 receptor antagonist, RP-67580, inhibits neurogenic inflammation postsynaptically. Br J Pharmacol 1993, 109: 259-64.
59. Sluka, K.A., Westlund, K.N. Spinal cord amino acid release and content in an arthritis model: The effects of pretreatment with non-NMDA, NMDA, and NK-1 receptor antagonists. Brain Res 1993, 627: 89-103.
60. Langdon, S., Sethi, T., Ritchie, A. et al. Broad spectrum neuropeptide antagonists inhibit the growth of small cell lung cancer in vivo. Cancer Res 1992, 52: 4554-7.
61. Mantyh, C.R., Vigna, S.R., Maggio, J.E., Mantyh, P.W., Bollinger, R.R., Pappas, T.N. Substance P binding sites on intestinal lymphoid aggregates and blood vessels in inflammatory bowel disease correspond to authentic NK-1 receptors. Neurosci Lett 1994, 178: 255-9.
62. Gygi, S.P., Gibb, J.W., Johnson, M., Hanson, G.R. Blockade of tachykinin NK-1 receptors by CP-96,345 enhances dopamine release and the striatal dopamine effects of methamphetamine in rats. Eur J Pharmacol 1993, 250: 177-80.
63. 2 receptor antagonist raclopride: Correlation with extracellular acethylcholine levels in striatum. J Pharmacol Exp Ther 1995, 274: 928-36.
64. Stratton, S.C., Beresford, I.J.M., Harvey, F.J., Turpin, M.P., Hagan, R.M., Tyers, M.B. Anxiolytic activity of tachykinin NK-2 receptor antagonists in the mouse light-dark box. Eur J Pharmacol 1993, 250: R11-2.
65. Dion, S., Rouissi, N., Nantel, F. et al. Receptors for neurokinins in human bronchus and urinary bladder are of the NK-2 type. Eur J Pharmacol 1990, 178: 215-9.
66. Giuliani, S., Barbanti, G., Turini, D. et al. NK-2 tachykinin receptors and contractions of circular muscle in the human colon: Characterization of the NK-2 receptor subtype. Eur J Pharmacol 1991, 203: 365-70.
67. Myers, A.C., Undem, B.J. Electrophysiological effects of tachykinins and capsaicin on guinea-pig bronchial parasympathetic neurons. J Physiol 1993, 470: 665-79.
68. Fuller, R.W., Conradson, T.-B., Dixon, C.M.S., Crossman, D.C., Barnes, P.J. Sensory neuropeptide effects in human skin. Br J Pharmacol 1987, 92: 781-8.
69. Couture, R., Kerouac, R. Plasma protein extravasation induced by mammalian tachykinins in rat skin: Influence of anaesthetic agents and an acetylcholine antagonist. Br J Pharmacol 1987, 91: 265-73.
70. McCarson, K.E., Krause, J. NK-1 and NK-3 type tachykinin receptor mRNA expression in the rat spinal cord dorsal horn is incresed during adjuvant or formalin-induced nociception. J Neurosci 1994, 14: 712-20.
71. Arenas, E., Alberch, J., Perez-Navarro, E., Solsona, C., Marsal, J. Neurokinin receptors differentially mediate endogenous acetylcholine release evoked by tachykinins in the neostriatum. J Neurosci 1991, 11: 2332-8.
72. Alonso, R., Fournier, M., Carayon, P., Petitpretre, G., Le Fur, G., Soubrié P. Evidence for modulation of dopamine-neuronal function by tachykinin NK-3 receptor stimulation in gerbil mesencephalic cell cultures. Eur J Neurosci 1996, 8: 801-8.
73. Stoessl, A.J., Dourish, C.T., Iversen, S.D. The NK-3 tachykinin receptor agonist senktide elicits 5-HT-mediated behaviour following central or peripheral administration in mice and rats. Br J Pharmacol 1988, 94: 285-7.
74. Stoessl, A.J., Dourish, C.T., Iversen, S.D. Pharmacological characterization of the behavioural syndrome induced by the NK-3 tachykinin agonist senktide in rodents: Evidence for mediation by endogenous 5-HT. Brain Res 1990, 517: 111-6.
75. Caeser, M., Seabrook, G.R., Kemp, J.A. Block of voltage-operated sodium currents by the substance P receptor antagonist (±)-CP-96,345 in neurones cultured from rat cortex. Br J Pharmacol 1993, 109: 918-24.
76. Lowe, J.A., Drozda, S.E., Snider, R.M., Longo, K.P., Rizzi, J.P. Nuclear variations of quinuclidine substance P antagonists: 2-Diphenylmethyl-1-azabicyclo[3.2.2]nonan-3-amines. Bioorg & Med Chem Lett 1993, 3: 921-4.
77. O'Neill, B.T. Pfizer Inc. WO 9300330.
78. Lowe, J.A., Drozda, S.E., McLean, S. et al. Aza-tricyclic substance P antagonists. J Med Chem 1994, 37: 2831-40.
79. Seward, E.M., Swain, C.J., Merchant, K.J. et al. Quinuclidine-based NK-1 antagonists 1: 3-Benzyloxy-1-azabicyclo[2.2.2]-octanes. Bioorg & Med Chem Lett 1993, 3: 1361-6.
80. Swain, C.J., Seward, E.M., Sabin, V. et al. Quinuclidine-based NK-1 antagonists 2: Determination of the absolute stereochemical requirements. Bioorg & Med Chem Lett 1993, 3: 1703-6.
81. Lowe, J.A., Ewing, F.E., Snider, R.M. et al. 2-Aryl-1-azabicyclo[2.2.2]octanes as novel nonpeptide substance P antagonists. Bioorg & Med Chem Lett 1994, 6: 839-42.
82. Swain, C.J., Fong, T.M., Haworth, S.N., Owen, S.N., Seward, E.M., Strader, C.D. Quinuclidine-based NK-1 antagonists, the role of the benzhydryl. Bioorg & Med Chem Lett 1995, 5: 1261-4.
83. Swain, C.J., Seward, E.M., Cascieri, M.A. et al. Identification of a series of 3-(benzyloxy)-1-azabiciclo[2.2.2]octane human NK-1 antagonists. J Med Chem 1995, 38: 4793-805.
84. Desai, M.C., Lefkowitz, S.L., Thadeio, P.F., Longo, K.P., Snider, R.M. Discovery of a potent substance P antagonist: Recognition of key molecular determinant. J Med Chem 1992, 35: 4911-3.
85. Desai, M.C., Thadeio, P.F., Lefkowitz, S.L. Synthesis of (±)-CP-99,994: A highly potent substance P antagonist. Tetrahedron Lett 1993, 34: 5831-4.
86. 3H]-cis-3-[(2-methoxy)benzylamino]-2-phenylpiperidine, a highly potent and selective substance P receptor antagonist radioligand. J Med Chem 1993, 36: 3197-201.
87. Fahy, J.V., Wong, H.F., Geppetti, P. et al. Effect of an NK-1 receptor antagonist (CP-99,994) on hypertonic saline-induced bronchoconstriction and cough in male asthmatic subjects. Am J Respir Crit Care Med 1995, 152: 879-84.
88. Bountra, C., Bunce, K.T., Dale, T. et al. The antiemetic profile of a non peptide neurokinin NK-1 receptor antagonist CP-99,994 in ferrets. Eur J Pharmacol 1993, 249: R3-4.
89. Tattersall, F.D., Rycroft, W., Hargreaves, R.J., Hill, R.G. The tachykinin NK-1 receptor antagonist CP-99,994 attenuates cisplatin induced emesis in the ferret. Eur J Pharmacol 1993, 250: R5-6.
90. Dionne, R.A., Max, M.B., Parada, S., Gordon, S.M., Maclean, D.B. Evaluation of a neurokinin 1 antagonist. CP-99,994, in comparison to ibuprofen and placebo in the oral surgery model. Clin Pharmacol Ther 1996, 59: 216.
91. Mclean, S., Fossa, A., Zorn, S., Rosen, T. Characterization of the interaction of the novel antagonist CP-122,721 with the NK-1 tachykinin receptor. Tachykinins '95 (Oct 16-18, Florence) 1995, 19.
92. Gonsalves, S., Watson, J., Ashton, C. Broad spectrum antiemetic effects of CP-122,721, a tachykinin NK-1 receptor antagonist in ferrets. Eur J Pharmacol 1996, 305: 181-5.
93. Kris, M.G., Radford, J., Pizzo, B. et al. Dose-ranging anti-emetic trial of the NK-1 receptor antagonist CP-122,721: A new approach for acute and delayed emesis following cisplatin. Proc Am Clin Oncol 1996, 15: A1780.
94. 1 receptor antagonist, (2S,3S)-(2-methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine (GR-203040), with potent antiemetic activity. J Med Chem 1995, 38: 4985-92.
95. Armour, D.R., Chung, K.M., Congreve, M. et al. Tetrazole NK-1 receptor antagonists: The identification of an exceptionally potent orally active antiemetic compound. Bioorg & Med Chem Lett 1996, 6: 1015-20.
96. Ward, P., Gardner, C.J., Twissel, D.J. et al. Tachykinin NK-1 antagonists: A new approach for the control of emesis. Peptide Receptors. An International Multidisciplinary Symposium. Montreal, Canada 1996, VII.O.2.
97. Harrison, T., Williams, B.J., Swain, C.J., Ball, R.G. Piperidine ether based hNK-1 antagonists 1: Determination of the relative and absolute stereochemical requirements. Bioorg & Med Chem Lett 1994, 4: 2545-50.
98. Hale, J.J., Mills, S.G., MacCoss, M. et al. 2(S)-((3,5-Bis(trifluoromethyl)benzyl) - oxy) - 3(S) -phenyl - 4 - ((3 - oxo - 1,2,4 - triazol-5-yl)methyl)morpholine (1): A potent, orally active, morpholine-based human neurokinin-1 receptor antagonist. J Med Chem 1996, 39: 1760-2.
99. Stevenson, G.I., MacLeod, A., Huscroft, I., Cascieri, M.A., Sadowski, S., Baker, R. 4,4-Disubstituted piperidines. A new class of NK-1 antagonist. J Med Chem 1995, 38: 1264-6.
100. Ladduwahetty, T., Baker, R., Cascieri, M.A. et al. N-Heteroaryl-2-phenyl-3-(benzyloxy)piperidines: A novel class of potent orally active human NK-1 antagonists. J Med Chem 1996, 39: 2907-14.
101. Mills, S.G., MacCoss, M., Underwood, D. et al. 1,2,3-Trisubstituted cyclohexyl substance-P antagonists: Significance of the ring nitrogen in piperidine-based NK-1 receptor antagonists. Bioorg & Med Chem Lett 1995, 5: 1345-50.
102. Mills, S.G., Wu, M.T., MacCoss, M. et al. 1,4-Diacylpiperazine-2-(S)-[(N-aminoalkyl)carboxamides] as novel, potent substance P receptor antagonists. Bioorg & Med Chem Lett 1993, 3: 2707-12.
103. Mills, S.G., MacCoss, M., Cascieri, M.A. et al. 1,2,4-Triacylpiperidine substance P antagonists: Separation of affinities for the NK-1 receptor and the L-type calcium channel. Bioorg & Med Chem Lett 1995, 5: 599-604.
104. Ofner, S., Hauser, K., Schilling, W., Vassout, A., Veenstra, S.J. SAR of 2-benzyl-4-aminopiperidines: CGP-49823, an orally and centrally active non-peptide NK-1 antagonist. Bioorg & Med Chem Lett 1996, 6: 1623-8.
105. Edmonds-Alt, X., Doutremepuich, J.D., Healulme, M. et al. In vitro and in vivo biological activities of SR-140,333, a novel potent non-peptide tachykinin NK-1 receptor antagonist. Eur J Pharmacol 1993, 250: 403-13.
106. Juranek, I., Lembeck, F. Influence of the tachykinin NK-1 receptor antagonist, SR-140,333, and of colchicine on functions mediated by afferent C-fibres in the rat. Proc Br Pharmacol 1994, P189.
107. Grisoni, S., Huon, C., Peyronel, J-F. 4,4-Diphenyl-7-perhydrothiapyrano[3,4-c]pyrrolone, a new series of substance P receptor antagonists. Bioorg & Med Chem Lett 1995, 5: 1591-4.
108. 1 antagonists. Bioorg & Med Chem Lett 1994, 4: 669-72.
109. 1 antagonist. Tetrahedron Lett 1996, 37: 7743-4.
110. 1 antagonists: The triarylperhydroisoindolols. Bioorg & Med Chem Lett 1994, 4: 673-6.
111. Moussaoui, S.M., Monttier, F., Carruette, A., Fardin, V., Floch, A., Garret, C. In vivo pharmacological properties of RPR-100893, a novel non-peptide antagonist of the human NK-1 receptor. Neuropeptides 1994, 26: 35 (C7/7).
112. Williams, B.J., Teall, M., McKenna, J. et al. Acyclic NK-1 antagonists: 2-Benzhydryl-2-aminoethyl ethers. Bioorg & Med Chem Lett 1994, 4: 1903-8.
113. Teall, M., Harrison, T., Moseley, J.D., Owens, A.P., Sadowski, S., Cascieri, M.A. Linear amides as substance P antagonists. Bioorg & Med Chem Lett 1996, 6: 1585-8.
114. Hipskind, P.A., Howbert, J.J., Bruns, R.F. et al. 3-Aryl-1,2-diacetamidopropane derivatives as novel and potent NK-1 receptor antagonists. J Med Chem 1996, 39: 736-48.
115. MacLeod, A.M., Cascieri, M.A., Merchant, K.J. et al. Synthesis and biological evaluation of NK-1 antagonists derived from L-tryptophan. J Med Chem 1995, 38: 934-41.
116. Natsugari, H., Ikeura, Y., Kiyota, Y. et al. Novel potent, and orally active substance P antagonists: Synthesis and antagonist activity of N-benzylcarboxamide derivatives of pyrido[3,4-b]pyridine. J Med Chem 1995, 38: 3106-20.
117. Fujii, T., Murai, M., Morimoto, H. et al. Pharmacological profile of a high affinity dipeptide NK-1 receptor antagonist. FK-888. Br J Pharmacol 1992, 107: 785-9.
118. Ichinose, M., Motohiko, M., Yamauchi, H. et al. A neurokinin 1 receptor antagonist improves exercise-induced airway narrowing in asthmatic patients. Am J Respir Crit Care Med 1996, 153: 936-41.
119. Boyle, S., Guard, S., Higginbottom, M. et al. Rational design of high affinity tachykinin NK-1 receptor antagonists. Bioorg & Med Chem Lett 1994, 2: 357-70.
120. Horwell, D.C. Use of the chemical structure of peptides as the starting point to design non-peptide agonists and antagonists at peptide receptors: Examples with cholecystokinin and tachykinins. Bioorg & Med Chem 1996, 4: 1573-6.
121. Advenier, C., Emonds-Alt, X., Vilain, P. et al. SR-48,968, a potent and selective non-peptide antagonist of the neurokinin A (NK-2) receptor. Br J Pharmacol 1992, 105: 77P.
122. Petitet, F., Beaujouan, J.-C., Saffroy, M., Torrens, Y., Glowinski, J. The nonpeptide NK-2 antagonist SR-48,968 is also a NK-3 antagonist in the guinea pig but not in the rat. Biochem Biophys Res Commun 1993, 191: 180-7.
123. Emonds-Alt, X., Proietto, V., Van Broeck, D. et al. Pharmacological profile and chemical synthesis of SR-48,968, a non-peptide antagonist of the neurokinin A (NK-2) receptor. Bioorg & Med Chem Lett 1993, 3: 925-30.
124. Selway, C.N., Terrett, N.K. Parallell-compound synthesis: Methodology for accelerating drug discovery. Bioorg & Med Chem 1996, 4: 645-54.
125. Kersey, I.D., Bhogal, N., Donnelly, D., Fishwick, C.W.G., Findlay, J.B.C., Ward, C. A non-peptidic photoactivable antagonist for mapping the antagonist binding site of the tachykinin NK-2 receptor. Bioorg & Med Chem Lett 1996, 6: 605-8.
126. Hale, J.J., Finke, P.E., MacCoss, M. A facile synthesis of the novel neurokinin A antagonist SR-48,968. Bioorg & Med Chem Lett 1993, 3: 319-22.
127. McElroy, A.B., Clegg, S.P., Deal, M.J. et al. Highly potent and selective heptapeptide antagonists of the neurokinin NK-2 receptor. J Med Chem 1992, 35: 2582-91.
128. Deal, M.J., Hagan, R.M., Ireland, S.J. et al. Conformationally constrained tachykinin analogues: Potent and highly selective neurokinin NK-2 receptor agonists. J Med Chem 1992, 35: 4195-204.
129. Smith, P.W., McElroy, A.B., Pritchard, J.M. et al. Low-molecular-weight neurokinin NK-2 antagonists. Bioorg & Med Chem Lett 1993, 3: 931-6.
130. Cooper, W.J., Adams, H.S., Bell, R. et al. GR159897 and related analogues as highly potent, orally active non-peptide neurokinin NK-2 receptor antagonists. Bioorg & Med Chem Lett 1994, 4: 1951-6.
131. Smith, P.W., Cooper, A.W., Bell, R. et al. New spiropiperidines as potent and selective non-peptide tachykinin NK-2 receptor antagonists. J Med Chem 1995, 38: 3772-9.
132. Jacobs, R.T., Mauger, R.C., Ulatowski, T.G., Aharony, D., Buckner, C.K. Substituted 2,4-diaminoquinazolines and 2,4-diamino-8-alkylpurines as antagonists of the neurokinin-2 (NK-2) receptor. Bioorg & Med Chem Lett 1995, 5: 2879-84.
133. Aharony, D., Buckner, C.K., Ellis, J.L. et al. Pharmacological characterization of a new class of nonpeptide neurokinin A antagonists that demonstrate species selectivity. J Pharmacol Exp Ther 1995, 274: 1216-21.
134. Boyle, S., Guard, S., Hodgson, J. et al. Rational design of high affinity tachykinin NK-2 receptor antagonists. Bioorg & Med Chem 1994, 2: 101-13.
135. Boden, P., Eden, J.M., Hodgson, J. et al. The rational development of small molecule tachykinin NK-3 receptor selective antagonists - The utilisation of a dipeptide chemical library in drug design. Bioorg & Med Chem Lett 1994, 4: 1679-84.
136. Boden, P., Eden, J.M., Hodgson, J. et al. The development of a novel series of non-peptide tachykinin NK-3 receptor selective antagonists. Bioorg & Med Chem Lett 1995, 5: 1773-8.
137. Boden, P., Eden, J.M., Hodgson, J. et al. Use of a dipeptide chemical library in the development of non-peptide tachykinin NK-3 receptor selective antagonists. J Med Chem 1996, 39: 1664-75.
138. Emonds-Alt, X., Bichon, D., Ducoux J.P. et al. SR-142,801, the first potent non-peptide antagonist of the tachykinin NK-3 receptor. Life Sci 1995, 56: PL 27-32.
139. Nguyen-Le, X.K., Nguyen, Q.T., Gobeil, F. et al. Pharmacological characterization of SR-142801: A new non-peptide antagonist of the neurokinin NK-3 receptor. Pharmacology 1996, 52: 283-91.
140. Giardina, G.A.M., Grugni, M., Rigolio, R., Vassallo, M., Erhard, K., Farina, C. A reliable and efficient synthesis of SR-142801. Bioorg & Med Chem Lett 1996, 6: 2307-10.
141. Chen, H.G., Chung, F.-Z., Goel, O.P. et al. A practical and scalable synthesis of SR-142801, a tachykinin NK-3 antagonist. Bioorg & Med Chem Lett 1997, 7: 555-60.
142. Shah, S.K. (Merck & Co. Inc.). US 5434158.
143. Giardina, G.A.M., Sarau, H.M., Farina, C. et al. 2-Phenyl-4-quinoline carboxamides: A novel class of potent and selective non-peptide competitive antagonists for the human neurokinin-3 receptor. J Med Chem 1996, 39: 2281-4.
144. Grugni, M., Farina, C., Giardina, G.A.M. et al. Potent and selective non-peptide NK-3 receptor antagonists based on the quinoline framework. XIVth Int Symp Med Chem (Sept 8-12, Maastricht) 1996, Abst P-2.15.
145. Giardina, G.A.M., Sarau, H.M., Farina, C. et al. Discovery of a novel class of selective nonpeptide antagonists for the human neurokinin-3 receptor. I. Identification of the 4-quinolinecarboxamide framework. J Med Chem 1997, 40: 1794-807.
146. Giardina, G.A.M., Farina, C., Foley, J.J. et al. SB-223412, a novel quinoline NK-3 receptor antagonist with high potency, selectivity and oral activity. XIVth Int Symp Med Chem (Sept 8-12, Maastricht) 1996, Abst OC-2/P-2.44.
147. Sarau, H.M., Griswold, D.E., Potts, W. et al. Nonpeptide tachykinin receptor antagonists. I. Pharmacological and pharmacokinetic characterization of SB-223412, a novel, potent and selective NK-3 receptor antagonist. J Pharmacol Exp Ther 1997, 281: 1303-11.
148. Takaya, T. Discovery of neurokinin antagonists. Pure Appl Chem 1996, 68: 875-80.
149. Ichinose, M., Nakajima, N., Takahashi, T. et al. Protection against bradykinin-induced bronchoconstriction in asthmatic patients by neurokinin receptor antagonist. Lancet 1992, 340: 1248-51.
150. Joos, G.F., Van Schoor, J., Kips, J.C., Pauwels, R.A. The effect of inhaled FK-224, a tachykinin NK-1 and NK-2 receptor antagonist on neurokinin A-induced bronchoconstriction in asthmatics. Am J Respir Crit Care Med 1996, 153: 1781-4.
151. Burkholder, T.P., Le, T.-B., Maynard, G.D., Shatzer, S.A., Knippenberg, R.W., Kudlacz, E.M. Identification and chemical synthesis of MDL-105,212, a non-selective, non-peptide tachykinin receptor antagonist. Tachykinins '95 Symposium (Oct 16-18, Florence) 1995, 21.
152. Burkholder, T.P., Kudlacz, E.M., Le, T.-B. et al. Identification and chemical synthesis of MDL-105,212, a non-peptide tachykinin antagonist with high affinity for NK-1 and NK-2 receptors. Bioorg & Med Chem Lett 1996, 6: 951-6.
153. Hale, J.J., MacCoss, M., Mills, S.G., Qi, H., Shah, S.K. (Merck & Co., Inc.). WO 9417045.
154. MacCoss, M., Mills, S.G., Shah, S.K. et al. (Merck & Co., Inc.). WO 9429309.
155. Chiang, Y.-C.P., Finke, P.E., MacCoss, M. et al. (Merck & Co., Inc.). WO 9610568.
156. Burkholder, T.P. Kudlacz, E.M., Le, T.-B. WO 9628441.
157. Burkholder, T.P., Le, T.-B., Kudlacz, E.M. WO 9632385.